EPISODE · Jul 19, 2017 · 3 MIN
Looking at the CAR-T Landscape As First Approval Nears
from GEN Podcasts
GEN Sounds of Science July 18, 2017Brad Loncar, CEO of Loncar Investments, discusses the outlook for chimeric antigen receptor T cell (CAR-T) cancer therapies as Novartis nears FDA approval for the first such treatment, CTL019. Some other CAR-T therapies have also shown early, yet promising, clinical data. Hosted on Acast. See acast.com/privacy for more information.
What this episode covers
GEN Sounds of Science July 18, 2017Brad Loncar, CEO of Loncar Investments, discusses the outlook for chimeric antigen receptor T cell (CAR-T) cancer therapies as Novartis nears FDA approval for the first such treatment, CTL019. Some other CAR-T therapies have also shown early, yet promising, clinical data. Hosted on Acast. See acast.com/privacy for more information.
NOW PLAYING
Looking at the CAR-T Landscape As First Approval Nears
No transcript for this episode yet
Similar Episodes
Jun 15, 2022 ·8m
May 25, 2022 ·20m
May 19, 2022 ·16m
May 15, 2022 ·34m
May 12, 2022 ·1m